New immune therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT07255664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ongoing management is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Krankenhaus Nordwest
RECRUITINGFrankfurt, 60488, Germany
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simpler chemo schedule tame colorectal cancer with fewer side effects?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Mini-Tumors grown in a dish could guide chemo choices for advanced colorectal cancer
- Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
- Could fasting help the immune system fight prostate cancer?